Literature DB >> 8258624

Cytokine profile of viral and autoimmune chronic active hepatitis.

A al-Wabel1, M al-Janadi, S Raziuddin.   

Abstract

BACKGROUND: Patients with hepatitis have multiple immunologic abnormalities, which may be related to cytokine production.
METHODS: We examined the in vitro production of interleukins (IL-2, IL-4, IL-6), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) in purified peripheral blood mononuclear cells (PBMCs) of patients with hepatitis B virus positive (HBV), acute viral hepatitis (A-HBV), HBV + chronic active hepatitis (HBV-CAH), and autoimmune-type chronic active hepatitis (AI-ACH).
RESULTS: IFN-gamma and TNF-alpha production were characteristically higher in patients with A-HBV than in healthy control subjects (p < 0.001). However, patients with AI-CAH produced highly elevated levels of IL-4 and IL-6 compared with patients with A-HBV and HBV-CAH and healthy control subjects. The cytokine profile (PBMC-induced IL-2, IL-4, IL-6, IFN-gamma, and TNF-alpha production) is different in A-HBV, HBV-CAH, and AI-CAH disease. The increased cytokine secretion (IFN-gamma and TNF-alpha in A-HBV and IL-4 and IL-6 in AI-CAH) could reflect altered relative frequencies of different cell phenotypes in these diseases.
CONCLUSIONS: Specific cytokine production may be important in the pathophysiology associated with diverse inflammatory states in patients with hepatitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258624     DOI: 10.1016/0091-6749(93)90068-q

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

Review 1.  Molecular pathways in virus-induced cytokine production.

Authors:  T H Mogensen; S R Paludan
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

2.  Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases.

Authors:  Francisca Monsalve-De Castillo; Tania A Romero; Jesús Estévez; Luciana L Costa; Ricardo Atencio; Leticia Porto; Diana Callejas
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

Review 3.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

4.  Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS.

Authors:  Feng Hong; Barbara Jaruga; Won Ho Kim; Svetlana Radaeva; Osama N El-Assal; Zhigang Tian; Van-Anh Nguyen; Bin Gao
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

5.  Nature and behavior of serum cytokines in type 1 autoimmune hepatitis.

Authors:  A J Czaja; C Sievers; N N Zein
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

6.  Analysis of serum cytokine levels in primary biliary cirrhosis patients and healthy adults.

Authors:  M Yamashiki; Y Kosaka; A Nishimura; S Watanabe; M Nomoto; F Ichida
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

7.  Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA.

Authors:  Robyn Puro; Robert J Schneider
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

Review 8.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

9.  Over-expression of uPA increases risk of liver injury in pAAV-HBV transfected mice.

Authors:  Xiao-Jun Zhou; Shi-Hui Sun; Peng Wang; Hong Yu; Jing-Ya Hu; Shi-Cheng Shang; Yu-Sen Zhou
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

10.  TaqMan real time RT-PCR assays for detecting ferret innate and adaptive immune responses.

Authors:  Louise A Carolan; Jeff Butler; Steve Rockman; Teagan Guarnaccia; Aeron C Hurt; Patrick Reading; Anne Kelso; Ian Barr; Karen L Laurie
Journal:  J Virol Methods       Date:  2014-05-04       Impact factor: 2.014

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.